Abstract：
Acute myocardial infarction (AMI) is a ubiquitous cardiovascular disease ensuing adverse prognosis caused by myocardial necrosis. Effective and rapid diagnosis of AMI is essential to following treatment in clinical practice while the existed biomarkers have inherent limitations. Consequently, exploration of novel biomarkers is needed. Long noncoding RNA (lncRNA) emerges as the upcoming biomarkers adopted in clinical use, and we aim at investigating the diagnostic power of lncRNA TTTY15 and HULC in AMI patients.
We measured lncRNA level in 80 AMI patients and 36 healthy volunteers in discovering cohort and 50 AMI patients and 20 healthy volunteers in verification cohort with quantitative RT-PCR method. Receiver operating characteristic (ROC) analysis was administered to detect the diagnostic power of selected lncRNAs. Regression and correlation analyses were performed to explore the related factors.
ROC analysis reveals the superiority of TTTY15 and HULC as biomarkers against conventional AMI biomarkers CKMB (AUC of TTTY15: 0.915 versus CKMB: 0.768 versus TnT: 0.869); AUC of HULC: 0.905 versus CKMB: 0.768 versus TnT: 0.869). Regression and correlation analysis indicates that TTTY15 and HULC may be one of the contributing factors to AMI and related to accepted risk factors.
Our results revealed the diagnostic potency of lncRNA TTTY15 and HULC, and they could also be treated as novel therapeutic targets in AMI therapy, hinting inspiration to the cardiologist in clinical practice.
We measured lncRNA level in 80 AMI patients and 36 healthy volunteers in discovering cohort and 50 AMI patients and 20 healthy volunteers in verification cohort with quantitative RT-PCR method. Receiver operating characteristic (ROC) analysis was administered to detect the diagnostic power of selected lncRNAs. Regression and correlation analyses were performed to explore the related factors.
ROC analysis reveals the superiority of TTTY15 and HULC as biomarkers against conventional AMI biomarkers CKMB (AUC of TTTY15: 0.915 versus CKMB: 0.768 versus TnT: 0.869); AUC of HULC: 0.905 versus CKMB: 0.768 versus TnT: 0.869). Regression and correlation analysis indicates that TTTY15 and HULC may be one of the contributing factors to AMI and related to accepted risk factors.
Our results revealed the diagnostic potency of lncRNA TTTY15 and HULC, and they could also be treated as novel therapeutic targets in AMI therapy, hinting inspiration to the cardiologist in clinical practice.
摘要：
急性心肌梗死（AMI）是一种普遍存在的心血管疾病，伴随着心肌坏死引起的不良预后。AMI的有效和快速诊断对于临床实践中的后续治疗至关重要，而现有的生物标志物具有固有的局限性。因此,需要探索新的生物标志物。长链非编码RNA（lncRNA）作为即将在临床使用中采用的生物标志物出现，我们旨在研究lncRNATTTY15和HULC在AMI患者中的诊断能力。
我们用定量RT-PCR方法检测了80例AMI患者和36例健康志愿者在发现队列中的lncRNA水平，50例AMI患者和20例健康志愿者在验证队列中的lncRNA水平。施用接受者操作特征(ROC)分析以检测选择的lncRNA的诊断能力。进行回归和相关分析，探讨相关因素。
ROC分析揭示TTTY15和HULC作为生物标志物相对于常规AMI生物标志物CKMB的优越性(TTTY15的AUC:0.915对CKMB:0.768对TnT:0.869);HULC的AUC:0.905对CKMB:0.768对TnT:0.869)。回归及相关分析显示TTTY15和HULC可能是AMI的促成因素之一，并与公认的危险因素有关。
我们的结果揭示了lncRNATTTY15和HULC的诊断效能，它们也可以作为AMI治疗的新治疗靶点，提示在临床实践中对心脏病学家的启发。
我们用定量RT-PCR方法检测了80例AMI患者和36例健康志愿者在发现队列中的lncRNA水平，50例AMI患者和20例健康志愿者在验证队列中的lncRNA水平。施用接受者操作特征(ROC)分析以检测选择的lncRNA的诊断能力。进行回归和相关分析，探讨相关因素。
ROC分析揭示TTTY15和HULC作为生物标志物相对于常规AMI生物标志物CKMB的优越性(TTTY15的AUC:0.915对CKMB:0.768对TnT:0.869);HULC的AUC:0.905对CKMB:0.768对TnT:0.869)。回归及相关分析显示TTTY15和HULC可能是AMI的促成因素之一，并与公认的危险因素有关。
我们的结果揭示了lncRNATTTY15和HULC的诊断效能，它们也可以作为AMI治疗的新治疗靶点，提示在临床实践中对心脏病学家的启发。
